# A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

> **NCT03748641** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 765 (actual)

## Conditions studied

- Castration-Resistant Prostatic Cancer

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone
- **DRUG:** Placebo
- **DRUG:** New Formulation of Niraparib and Abiraterone Acetate (AA)

## Key facts

- **NCT ID:** NCT03748641
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-01-25
- **Primary completion:** 2021-10-08
- **Final completion:** 2027-02-27
- **Target enrollment:** 765 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03748641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03748641, "A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-08-15 from https://api.ai-analytics.org/clinical/NCT03748641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*